Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Case Rep ; 11(9): e7856, 2023 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-37720706

RESUMO

We report a case of arterial and venous thrombosis during induction therapy. This case emphasizes considering some degree of caution for thrombotic events in APL patients which was represented in our case as abdominal pain. Rapid initiation of anticoagulation and preventive measures is suggested for better management of the condition.

2.
Heliyon ; 9(6): e17370, 2023 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-37350773

RESUMO

Background: The covid-19 disease has caused many deaths worldwide since December 2019. Many thromboembolic events, such as VTE and TTP, have been reported since the beginning of this pandemic. Considering the prominent role of complement in developing TTP and TTP-like syndrome in recent studies, this study aimed to assess the prevalence of TTP-like syndrome and its relationship with complement activity in critically ill patients with COVID-19. Method: This study was conducted on 77 COVID-19 patients admitted to the ICU wards of Tabriz Imam Reza hospital from March to June 2021. TTP-like syndrome was diagnosed using a blood specimen for evidence of thrombocytopenia, microangiopathic hemolysis (low hemoglobin, increased LDH level, schistocytes in a peripheral blood smear, and negative direct agglutination test), and end-organ injury, including acute kidney injury or neurological deficit. ADAMTS 13 activity levels could not be achieved owing to logistic issues; therefore, we could not accurately diagnose TTP and TTP-like syndrome based on ADAMTS 13 levels, so to increase the accuracy of diagnosis, we have included people with classical pentad evidence in the TTP-like syndrome group. Complement parameters, including C3, C4, and CH50, were measured. Result: Seven cases of TTP-like syndrome were diagnosed using the previously mentioned criteria, which stands for 9.1% of the study population. Compared with patients without TTP-like syndrome, C3 was significantly lower in patients with TTP-like syndrome (p-value = 0.014), and C4 and CH50 demonstrated insignificant differences between the two groups (p-value = 0.46, p-value = 0.75). Conclusion: Our study showed that the TTP-like syndrome was present in a significant percentage of critically ill patients with COVID-19. Lower C3 levels in TTP-like syndrome-diagnosed patients can indicate complement activation as one of the influential factors in initiating TTP-like syndrome in COVID-19 patients. More studies are recommended to clarify the exact mechanism to achieve adequate therapeutic methods and better manage the disease and its complications.

3.
Clin Rheumatol ; 42(6): 1537-1544, 2023 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-36800137

RESUMO

OBJECTIVES: The aim of the present study was to provide real-world evidence for factors predicting long-term remission in a longitudinal study of rheumatoid arthritis (RA) patients. METHODS: Long-term remission was defined by meeting American Rheumatism Association (ARA) criteria for remission and prednisolone dose ≤ 5 mg/d for at least 5 years. Patients in this cohort were treated by tight control strategy using step-up combination therapy with conventional synthetic DMARDs (csDMARDs), biologic DMARDs. The parameters associated with long-term remission were subjected to univariate analysis, and parameters with P-values of < 0.1 in univariate analysis were included in a multivariate regression analysis. RESULTS: One thousand two hundred and eighty-six RA subjects were considered for eligibility, and finally, 499 patients were included in the study. Median duration of follow-up was 108 months. Long-term remission occurred in 157 (31.5%) patients. Median time to long-term remission was 8 (5, 41) months. Predictors of long-term remission were absence of flare during the course of disease, occurrence of sustained remission during 6 months after starting therapy, age at the disease onset > 60, being anti-citrullinated protein antibodies (ACPA) negative, and Disease Activity Score-28 (DAS28) at cohort entry ≤ 5.1. CONCLUSION: In real-world practice, long-term remission occurs in 31.5% of patients treated with a tight control strategy. Absence of flare during the course of disease, occurrence of sustained remission during 6 months after starting therapy, age at the disease onset > 60, being ACPA negative, and DAS28 at baseline ≤ 5.1 are independent predictors of long-term remission. Key Points • In real-world practice, long-term remission occurs in 31.5% of patients treated with a tight control strategy. • Median time to long-term remission was 8 months. • Absence of flare during the course of disease, occurrence of sustained remission during 6 months after starting therapy, age at the disease onset >60, being ACPA negative, and DAS28 at baseline ≤ 5.1 are independent predictors of long-term remission.


Assuntos
Antirreumáticos , Artrite Reumatoide , Humanos , Estudos Longitudinais , Prevalência , Resultado do Tratamento , Indução de Remissão , Artrite Reumatoide/epidemiologia , Antirreumáticos/uso terapêutico
4.
Clin Case Rep ; 10(9): e6288, 2022 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-36093464

RESUMO

Systemic lupus erythematosus (SLE) is an autoimmune disease and may be associated with many autoimmune conditions. Hypoparathyroidism is a rare disease. The leading cause of hypoparathyroidism is postsurgical hypoparathyroidism. However, hypoparathyroidism as an initial presentation of SLE is still a rare condition. Here, we report a case of SLE presented with hypoparathyroidism and Hashimoto's thyroiditis.

5.
Gene ; 834: 146668, 2022 Aug 05.
Artigo em Inglês | MEDLINE | ID: mdl-35690284

RESUMO

Lung cancer represents a significant global health issue and is among the central causes of mortality and morbidity around the world. Unfortunately, the majority of lung cancer patients acquire drug resistant to chemotherapy either intrinsically or acquired after Cisplatin treatment. It is indicated that increasing or decreasing the expression of particular genes can affect chemotherapeutic sensitivity or resistance. As a result, gaining a deeper knowledge of the changed expression of genes implicated in lung cancer drug resistance, as well as developing novel therapeutic techniques, are critical targets for continued advancement in lung cancer treatment. In the present study, we aimed to find key regulatory genes in the progression of Cisplatin resistance in A-549 lung cancer cells. In this regard, microarray dataset of Cisplatin-resistant and Cisplatin-sensitive was retrieved from the Gene Expression Omnibus (GEO) with accession number of GSE108214. Then, differentially expressed genes (DEGs) between sensitive and resistant lung cancer cells were obtained by using R software v4.0.2 and related packages. We recognized CEACAM1, DGKA, ARHGEF4, and THSD4 are involved in the drug resistance. Experimentally, Cisplatin-resistant A-549 cells were developed and analyzed by MTT assay. Besides, the expression of candidate genes were analyzed in these cells compared to Cisplatin-sensitive A-549 cells by qRT-PCR. The findings presented that the expression of CEACAM1, DGKA, ARHGEF4, and THSD4 was altered following the induction of Cisplatin resistance in A549 cells.


Assuntos
Antineoplásicos , Neoplasias Pulmonares , Células A549 , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Apoptose , Linhagem Celular Tumoral , Cisplatino/farmacologia , Biologia Computacional , Resistencia a Medicamentos Antineoplásicos/genética , Regulação Neoplásica da Expressão Gênica , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Fatores de Troca de Nucleotídeo Guanina Rho/genética , Fatores de Troca de Nucleotídeo Guanina Rho/metabolismo
6.
Inflammopharmacology ; 30(4): 1277-1282, 2022 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-35723849

RESUMO

Cytokine storm is the most prominent hallmark in patients with coronavirus disease 2019 (COVID-19) that stimulates the free radical storm, both of which induce an overactive immune response during viral infection. We hypothesized that owning to its radical-scavenging and anti-inflammatory properties, Edaravone could reduce multi-organ injury, clinical complications, and mortality in severe COVID-19 cases. This single-center randomized clinical trial was accompanied in the intensive care units (ICUs) of the teaching hospital of Tabriz University of Medical Sciences to evaluate the effect of Edaravone on the outcome of patients with severe COVID-19. Thirty-eight patients admitted to ICU were included and randomized into two control and intervention arms. Patients in the intervention group received 30 mg Edaravone by slow intravenous infusion for three days in addition to receiving national therapy. The primary outcome was the need for intubation, the intubation length, and mortality rate. Secondary endpoints were clinical improvement. Edaravone administration improved the primary outcomes; it decreased the need for endotracheal intubation and mechanical ventilation [10.52% (n = 2) versus 42.1% (n = 8); p = 0.03] and intubation length [3 (1-7) versus 28 (4-28), p = 0.04] compared to control group. Baseline characteristics and laboratory tests were similar between the studied groups. No marked differences were observed in secondary endpoints (p > 0.05). Administration of Edaravone could decrease the need for mechanical ventilation and length of intubation in severe COVID-19 patients admitted to ICU.


Assuntos
Tratamento Farmacológico da COVID-19 , Síndrome da Liberação de Citocina , Edaravone , Humanos , Unidades de Terapia Intensiva , SARS-CoV-2
7.
BMC Infect Dis ; 22(1): 217, 2022 Mar 03.
Artigo em Inglês | MEDLINE | ID: mdl-35241013

RESUMO

BACKGROUND: Ever since the administration of early doses of COVID-19 vaccines, instances of adverse effects have been reported. Viral infections, specifically herpes simplex reinfection and coinfections, have been reported following administration of different types of vaccines. To our knowledge, there have not been any reports of herpes simplex encephalitis following administration of any type of COVID-19 vaccine to date. CASE PRESENTATION: In this article intends to report a case of herpes simplex encephalitis in a 27-year-old male patient who was vaccinated with the ChAdOx1 nCoV-19 vaccine. CONCLUSIONS: Our study suggests a possible but very rare side effect of ChAdOx1 nCoV-19 vaccine, which requires immediate medical attention and can lead to devastating consequences if left undiagnosed and untreated.


Assuntos
COVID-19 , Encefalite por Herpes Simples , Adulto , Vacinas contra COVID-19/efeitos adversos , ChAdOx1 nCoV-19 , Encefalite por Herpes Simples/diagnóstico , Encefalite por Herpes Simples/etiologia , Humanos , Masculino , SARS-CoV-2 , Vacinação/efeitos adversos
8.
Natl J Maxillofac Surg ; 13(3): 357-361, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36683935

RESUMO

Context: The relationship between olfactory and gustatory dysfunction (OGD) and COVID-19 infection severity is still unclear. Aim: To investigate the correlation between OGD in COVID-19-infected individuals and RT-PCR results, chest CT scan abnormality, lymphocyte counts, hospital admission units, age, body temperature, and blood oxygen saturation. Setting and Design: Case-control study. Materials and Methods: The sample was composed of laboratory and chest X-ray confirmed COVID-19-infected patients from four hospitals. The patients were divided into case and control groups based on the presence of OGD symptoms. The predictor variable was OGD. The outcome variable was gender, hospital admission unit, chest CT scan abnormality, PCR, lymphocyte counts, age, body temperature, and blood oxygen saturation. Statistical Analysis Used: Bivariate statistics were computed and the P value was set at 0.05. Results: The sample consisted of 189 patients. Smell and taste disorders were found in 31.7% and 24.3% of patients, respectively. OGD was significantly correlated with positive PCR results (P < 0.001) and general unit admission (P < 0.05) during hospitalization. Additionally, patients with OGD had significantly lower mean age (P < 0.001), higher body temperature (P < 0.01), and blood oxygen saturation (P < 0.01). However, OGD was not correlated with gender, chest CT scan abnormality, or lymphocyte counts (P > 0.05). Conclusions: OGD symptoms can be used to detect COVID-19-infected patients. OGD can be used to predict less severe disease mainly by its correlation with the less amount of hospital care, more negative PCR results, higher body temperature, and higher blood oxygen saturation.

9.
Clin Case Rep ; 9(11): e05101, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34824852

RESUMO

More attention of the medical staff to this sign can lead to faster diagnosis and timely treatment of patients.

10.
Environ Eng Sci ; 29(12): 1092-1096, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23236251

RESUMO

Effects of pH and the addition of calcium chloride (CaCl(2)) on bromate (BrO(3) (-)) and bromide (Br(-)) rejection by a ceramic membrane were investigated. Rejection of both ions increased with pH. At pH 8, the rejection of BrO(3) (-) and Br(-) was 68% and 63%, respectively. Donnan exclusion appears to play an important role in determining rejection of BrO(3) (-) and Br(-). In the presence of CaCl(2), rejection of BrO(3) (-) and Br(-) ions was greatly reduced, confirming the importance of electrostatic interactions in determining rejection of BrO(3) (-) and Br(-). The effect of Ca(2+) is so pronounced that in most natural waters, rejection of both BrO(3) (-) and Br(-) by the membrane would be extremely small.

11.
Water Res ; 45(17): 5529-34, 2011 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-21875738

RESUMO

The effect of pH, ozone mass injection rate, initial bromide concentration, and membrane molecular weight cut off (MWCO) on bromate formation in a hybrid membrane filtration-ozonation reactor was studied. Decreasing the pH, significantly reduced bromate formation. Bromate formation increased with increasing gaseous ozone mass injection rate, due to increase in dissolved ozone concentrations. Greater initial bromide concentrations resulted in higher bromate concentrations. An increase in the bromate concentration was observed by reducing MWCO, which resulted in a concomitant increase in the retention time in the system. A model to estimate the rate of bromate formation was developed. Good correlation between the model simulation and the experimental data was achieved.


Assuntos
Bromatos/síntese química , Cerâmica/química , Filtração/métodos , Membranas Artificiais , Ozônio/química , Bromatos/química , Filtração/instrumentação , Concentração de Íons de Hidrogênio , Radical Hidroxila/química , Cinética , Modelos Químicos , Peso Molecular , Permeabilidade , Solubilidade , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...